BioNTech’s oncology vaccine trial sees all patients living kidney cancer-free
Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.
Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.
Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and ...
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...
RFK Jr. HHS nomination advances out of Senate Finance Committee
The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...
BioNTech price target lowered to $147 from $150 at BofA
BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...
InvestorsHub on MSN2d
Moderna, BioNTech Shares Down After Senate Committee Vote To RFK Jr.’s Nomination
The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...
BioNTech Completes Acquisition of Biotheus
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...
Politifact7d
No, Pfizer didn’t release a new list of COVID-19 vaccine side effects
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook
BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...
Peering Into BioNTech's Recent Short Interest
According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...